Grants for Public and State controlled institutions of higher education - Science and Technology

Grant Opportunity: New York Newspapers Foundation The New York Newspapers Foundation is offering financial support to organizations that align with its mission of promoting freedom of speech and the press, as well as education and scientific research related to these fields. The foundation was established in 1977 by the New York State Publishers Association and is a public organization with 501(c)(3) status. Eligible applicants for this grant opportunity include nonprofits, startups, researchers, local governments, small businesses, and any other organization that focuses on the dissemination of information. To apply for funding, interested organizations need to complete the provided form and submit it to the address specified at the bottom of the form. Please note that eligibility is not guaranteed unless explicitly stated in the application guidelines or requirements.

Supports research on the magnetized plasma envelope of the outer atmosphere, including energization by the solar wind; the origin of geomagnetic storms and substorms; the population by solar and ionospheric sources; the origin of electric fields; the coupling among the magnetosphere, ionosphere, and atmosphere; and waves and instabilities in the natural plasma. Also supported are ground-based observational programs at high latitudes and laboratory experiments applicable to the geospace environment. Theoretical research programs may include numerical simulations using a variety of MHD, hybrid and particle codes. The analysis of data from all sources, whether ground-based or from spacecraft, is also supported.

Synthesis Centers are a mechanism used by NSF's Directorate for Biological Science (BIO) to bring together communities that leverage existing data to catalyze discoveries through synthesis, analysis, and integrative training. Research supported by the Division of Integrative Organismal Systems (IOS) in BIO focuses on organisms as integrated units of biological organization, i.e., why they are structured as they are and function as they do. IOS seeks to establish a new Synthesis Center to advance our ability to explain and predict organismal resiliency and plasticity in response to complex and dynamic environmental circumstances encountered over a lifespan through the synthesis of varied data sets and types that bridge multiple scales and levels. The Synthesis Center will enable innovative synthesis and analysis of available biological and related data by providing the vision, infrastructure, and expertise to advance new avenues of inquiry in organismal biology focused on organismal resilience and plasticity. To accomplish this vision, the Synthesis Center will adopt approaches that are based on open science, team science, and data-intensive methods that enable data synthesis, sharing and inclusive collaborations among researchers across multiple levels of biological inquiry that may include genomic, physiological, structural, developmental, behavioral, neural, immunological, and microbiological analyses across some or all the IOS subdisciplines. In addition to supporting data and knowledge synthesis, the Synthesis Center should train new generations of researchers in solving challenging research problems through data-intensive, open, cross-disciplinary, and collaborative science. The Synthesis Center is also expected to serve as an example in effectively engaging diverse scientists from different types of institutions and across multiple disciplines. These types of data syntheses are expected to provide the basis for fundamental scientific discoveries and/or potentially translational, use-inspired research. In doing so, the Synthesis Center will have a profound impact on the progress of science and society.

Microbes and communities of microbes have remarkable genetic, physiological and biochemical diversity, allowing them to flourish in environments all over the planet and in a variety of substrates and hosts. Given their relative importance to ecosystems around the world, to the economy and to health, researchers have studied microbial systems extensively and have a better understanding of their capabilities and impacts on hosts and the environment. In recent years, researchers have increasingly turned to microbes and their diverse capabilities for bioremediation and applications in biotechnology, agriculture, and medicine. Because of advances in molecular biology, synthetic biology and bioengineering, researchers now have the ability to assemble synthetic microbial communities that have novel compositions, genetics and phenotypes and to use these communities to address both fundamental biological questions and a range of societal problems. The goal of this solicitation is to support research that addresses one or more of the three themes: 1) define the underlying mechanisms or rules that drive the formation, maintenance or evolution of synthetic microbial communities, 2) use synthetic microbial communities to address fundamental biological questions, including questions in molecular biology, cellular/organismal biology, ecology and evolution and/or 3) build synthetic communities with biotechnology, bioeconomy or environmental engineering applications, including but not limited to the production of novel biorenewable chemicals, biodegradation of recalcitrant or forever chemicals, enabling a circular bioeconomy, fostering sustainable agriculture and mitigating the impacts of climate change. For theme 3, the emphasis should be on designing communities with novel capabilities and understanding the underlying mechanisms that lead to these novel capabilities. Proposals must address one or more of the three themes noted above. Highest funding priority is given to proposals that have outstanding intellectual merit and broader impacts, while proposals with weaknesses in either category (or those that are perceived as likely to have an incremental impact) will not be competitive. The most competitive broader impacts include assessment plans. Well-conceived broader impacts activities take time and resources; thus, proposers are encouraged to include appropriate costs for broader impacts in the budget. To better understand the societal benefits and risks, as well as the potential for misuse or unintended damage to natural biological systems, synthetic microbial communities proposals should include a careful consideration of the social, ethical, and biosafety/security dimensions of the research. Investigators may choose to address these issues either as part of intellectual merit or broader impacts. Reproducibility in research leads to data that is amenable to more powerful analysis and the potential for reuse of data and greater generation of knowledge. Reproducibility in biological research that is prone to context dependent biological variation presents a unique challenge for the synthetic microbial communities researchers. Investigators must follow or advance best practices in sample collection and preparation, experimental design, data analysis, model generation, and/or validation of mathematical and computational methods to produce scientifically defensible results.

This grant provides funding for researchers in applied mathematics to develop innovative mathematical techniques that address challenges in science and engineering, excluding biological applications.

This funding opportunity provides financial support for research and development projects focused on improving battery technologies, particularly for electric vehicles, and is open to a wide range of applicants including educational institutions, nonprofits, and government entities.

This grant provides funding for early-career researchers to explore the economic impacts of Alzheimer's disease and related dementias, supporting innovative studies on prevention, treatment, and care for affected individuals.

To implement a project aimed at advancing U.S. foreign policy and national security priorities outlined in the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act of 2022 (Div. A, P.L. 117-167). The Act established a new International Technology Security and Innovation Fund (ITSI Fund) to to support the development and adoption of secure semiconductors, [and] semiconductor supply chains with the goal to make the global semiconductor supply chain more resilient, diversified, and secure.

The DoD Psychedelic Treatment Research Clinical Trial Award is a funding opportunity aimed at supporting clinical trials that evaluate the use of specific psychedelic substances in treating U.S. Service Members diagnosed with post-traumatic stress disorder (PTSD) and/or traumatic brain injury (TBI), with the goal of advancing research beneficial to Service Members, Veterans, and their families.

Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Department of Defense Trauma Registry. Additionally, orthopaedic injuries and conditions that occur outside of combat (e.g., during training, leisure activities, resultant from old injuries, etc.) present one of the greatest threats to the readiness of our Service Members and military. Early stabilization, treatment, and rehabilitation of orthopaedic injuries in both civilian and military populations have led to better outcomes, particularly in the prevention of secondary complications and in minimizing morbidity. Availability of orthopaedic care and treatment as early as possible, or as close to the point of injury as possible, also minimizes limb loss and affects military readiness.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the selected Focus Area.The FY24 PRORP ARA seeks applied research applications focused on advancing optimal treatment and restoration of function for individuals with orthopaedic injuries sustained during combat and service-related activities. Applicants are encouraged to address how the proposed research will support patient care and allow patients to more quickly return to duty/work. It is expected that any research findings would also provide benefit to the general population. To meet the intent of the award mechanism, applications must specifically address an FY24 PRORP ARA Focus Area, listed in Section II.A.1, above.The FY24 PRORP ARA is focused on applied research, defined as work that refines concepts and ideas into potential solutions with a view toward evaluating technical feasibility of promising new knowledge products, pharmacologic agents, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance, and/or emerging approaches and technologies.Awards may not be used to support fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind.Research Scope: Research proposed under the FY24 PRORP ARA may include small- to large-scale projects. Upon successful completion, the proposed research is expected to yield knowledge products, approaches, or technologies that have the potential to advance toward clinical translation. Strong transition plans are expected.Inclusion of preliminary and/or published data relevant to the proposed research is required. Applicants must demonstrate logical reasoning for the proposed work. To be competitive, the application must include a sound scientific rationale and a well-formulated, testable hypothesis established through a critical review and analysis of the literature.Studies allowed under the FY24 PRORP ARA may include, but are not limited to: Refinement of concepts and ideas into potential solutions, or research tools, with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new knowledge products. Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic constructs, or devices/systems) in vitro and/or in vivo. Preparation activities needed to support a future clinical trial or regulatory submission.Applications to the FY24 PRORP ARA mechanism must support preclinical applied research and may not be used for clinical research studies. Applicants seeking support for clinical research projects should consider the FY24 PRORP Clinical Translational Research Award (Funding Opportunity Number HT942524PRORPCTRA), Clinical Trial Award (Funding Opportunity Number HT942524PRORPCTA), or Womens Health Research Award (Funding Opportunity Number HT942524PRORPWHRA) mechanisms.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment 8, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE guidelines 2.0 (Animal Research: Reporting In Vivo Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.Womens Health Research: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health. Applications proposing research that solely address womens health may also consider the FY24 PRORP WHRA mechanism, Funding Opportunity Number HT942524PRORPWHRA.Encouraged Department of Defense (DOD) and/or VA Collaboration: Military relevance is a key feature of this award. Principal Investigators (PIs) are encouraged, but not required, to collaborate with DOD or VA researchers and clinicians.Use of DOD or VA Resources: If the proposed research involves access to DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP Applied Research Award should not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $3.75M to fund approximately five ARA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The Biomedical Research Grant (BRG) program at Indiana University School of Medicine (IUSM) is designed for full-time faculty members across all tenure statuses, supporting both new and established researchers. It aims to facilitate the acquisition of preliminary data for those without extramural funding and to assist established investigators in bridging funding gaps. The program offers small grants up to $50,000 for one-year projects. Applicants must have less than $100,000 in direct cost extramural funding to be eligible, focusing on providing interim technical support for research projects.

This grant provides funding for researchers to develop innovative statistical methods and models that enhance data analysis and interpretation across various scientific and engineering fields.

This grant provides funding for early career researchers in planetary science to conduct innovative research that aligns with NASA's mission to advance our understanding of space and Earth systems.

This grant provides funding to collaborative groups focused on improving undergraduate biology education by integrating research discoveries with innovative teaching practices, particularly emphasizing inclusivity and diverse perspectives.

This grant provides funding to a single organization to lead and manage a national initiative that connects researchers and educators with essential artificial intelligence resources and infrastructure.

This funding opportunity supports alumni of U.S. government-sponsored exchange programs in Lebanon to implement innovative projects that promote good governance, social cohesion, and cultural heritage while encouraging diversity and inclusion.

This funding opportunity provides financial support for large-scale marine debris removal projects that enhance the resilience of coastal and marine environments, benefiting local communities and economies.

This grant provides funding for innovative research aimed at developing new methods and tools to protect military personnel from diseases transmitted by insects, while also improving pest control strategies for bed bugs and filth flies.

Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Department of Defense Trauma Registry. Additionally, orthopaedic injuries and conditions that occur outside of combat (e.g., during training, leisure activities, resultant from old injuries) present one of the greatest threats to the readiness of our Service Members and military. Early stabilization, treatment, and rehabilitation of orthopaedic injuries in both civilian and military populations have led to better outcomes, particularly in the prevention of secondary complications and in minimizing morbidity. Availability of orthopaedic care and treatment as early as possible, or as close to the point of injury as possible, also minimizes limb loss and affects military readiness.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the selected Focus Area.The PRORP CTRA is intended to support high-impact and/or emerging clinical research that may not be ready for a full-scale randomized controlled clinical trial. Projects should demonstrate potential to impact the standard of care, both immediate and long-term, as well as contribute to evidence-based guidelines for the evaluation and care of military, Veterans, and all patients with orthopaedic injuries. One goal of the FY24 PRORP CTRA is to translate current and emerging techniques and interventions into the clinical space to better serve military and non-military patients. A holistic approach that takes into account the health, functional abilities, and quality of life of individuals who have sustained an orthopaedic injury should be considered. Another goal is to identify the most effective diagnosis, treatment, rehabilitation, and prevention options available to support critical decision-making for patients, clinicians, other caregivers, and policymakers.The FY24 PRORP CTRA differs from the FY24 PRORP Clinical Trial Award (CTA) in that the CTRA allows for clinical research projects that may or may not include a clinical trial, whereas the CTA is restricted to clinical trials only.Funding from this award mechanism must support clinical research and may not be used for animal research.Clinical research encompasses research with patient samples, data, and interaction with patients that may or may not be considered a clinical trial. Clinical research is observational in nature and includes: (1) Research that does not seek to evaluate the effects of interventions. Research conducted with human subjects (or on material of human origin such as data, tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects but does not seek to assess the effects of an intervention, qualifies as clinical research. Patient-oriented research may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to study the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human tissues that cannot be linked to a living individual. Note: Studies that meet the requirements for exemption under 46.104(d)(4) of the Common Rule are not considered clinical research as defined by the CDMRP. Exemption category 4 refers to secondary research for which consent is not required.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.Proposed studies submitted to the CTRA may be interventional and may involve some retrospective data analysis. Note that purely retrospective or database-related research is not allowed under this funding opportunity. Small pilot clinical trials with human subjects are allowable.Key aspects of the PRORP CTRA mechanism: Preliminary Data Are Required: Inclusion of preliminary data relevant to the proposed clinical research is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical research appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If proposing a clinical trial that requires oversight by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted.If the proposed clinical research involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an Investigational New Drug (IND) application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant Regulatory Agency within 12 months of the CTRA award start date. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an Investigational Device Exemption (IDE), or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency within 12 months of the CTRA award start date. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.Womens Health: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health. Applications proposing research that solely address womens health may also consider the FY24 PRORP WHRA mechanism, Funding Opportunity Number HT942524PRORPWHRA.Use of Department of Defense (DOD) or VA Resources: If the proposed research involves access to DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP CTRA should not exceed $1.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $6.0M to fund approximately four CTRA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The GIVE Washington County Fund Grants, offered by the Washington County Community Foundation in Pennsylvania, is inviting applications from eligible nonprofits, governmental or educational institutions for a flexible grant of up to $10,000, to be used in eight focus areas including animal welfare, arts, community improvement, conservation, education, health, human needs, and religion, excluding general operating or routine program support.